SMP200900023B - Benzossazoli e ossazolopiridine utili come inibitori di chinasi janus - Google Patents

Benzossazoli e ossazolopiridine utili come inibitori di chinasi janus

Info

Publication number
SMP200900023B
SMP200900023B SM200900023T SM200900023T SMP200900023B SM P200900023 B SMP200900023 B SM P200900023B SM 200900023 T SM200900023 T SM 200900023T SM 200900023 T SM200900023 T SM 200900023T SM P200900023 B SMP200900023 B SM P200900023B
Authority
SM
San Marino
Prior art keywords
oxazolopyridines
benzoxazoles
inhibitors
useful
janus
Prior art date
Application number
SM200900023T
Other languages
English (en)
Other versions
SMAP200900023A (it
Inventor
Pascal Furet
Marc Gerspacher
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP200900023(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMAP200900023A publication Critical patent/SMAP200900023A/it
Publication of SMP200900023B publication Critical patent/SMP200900023B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM200900023T 2006-09-15 2009-04-09 Benzossazoli e ossazolopiridine utili come inibitori di chinasi janus SMP200900023B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
PCT/EP2007/007983 WO2008031594A1 (en) 2006-09-15 2007-09-13 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Publications (2)

Publication Number Publication Date
SMAP200900023A SMAP200900023A (it) 2009-05-11
SMP200900023B true SMP200900023B (it) 2009-07-14

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
SM200900023T SMP200900023B (it) 2006-09-15 2009-04-09 Benzossazoli e ossazolopiridine utili come inibitori di chinasi janus

Country Status (30)

Country Link
US (1) US8629168B2 (it)
EP (2) EP1900729A1 (it)
JP (1) JP5325105B2 (it)
KR (1) KR20090064389A (it)
CN (1) CN101516860B (it)
AR (1) AR062786A1 (it)
AT (1) ATE532774T1 (it)
AU (1) AU2007296916B2 (it)
BR (1) BRPI0716841A2 (it)
CA (1) CA2660987A1 (it)
CL (1) CL2007002669A1 (it)
CO (1) CO6150142A2 (it)
CR (1) CR10639A (it)
EA (1) EA200900388A1 (it)
ES (1) ES2377148T3 (it)
GT (1) GT200900056A (it)
IL (1) IL196860A0 (it)
MA (1) MA30723B1 (it)
MX (1) MX2009002812A (it)
NO (1) NO20091469L (it)
PA (1) PA8748101A1 (it)
PE (1) PE20080842A1 (it)
PL (1) PL2066647T3 (it)
PT (1) PT2066647E (it)
SM (1) SMP200900023B (it)
TN (1) TN2009000070A1 (it)
TW (1) TW200819444A (it)
UY (1) UY30587A1 (it)
WO (1) WO2008031594A1 (it)
ZA (1) ZA200900477B (it)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
EP2318415B1 (en) * 2008-07-15 2013-02-20 Sanofi Oxazolopyrimidines as edg-1 receptor agonists
US20100041891A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010061971A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ピリジン－３－カルボキシアミド誘導体
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
JP6615983B2 (ja) 2015-08-03 2019-12-04 クワドリガ バイオサイエンシーズ， インコーポレイテッド 化学療法剤としてのβ置換βアミノ酸および類似体ならびにそれらの使用
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1382339E (pt) * 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
ATE497959T1 (de) * 2005-09-02 2011-02-15 Hoffmann La Roche Benzoxazol-, oxazolopyridin-, benzothiazol- und thiazolopyridinderivate
CN101506177A (zh) * 2006-07-21 2009-08-12 诺瓦提斯公司 作为jak激酶抑制剂的2,4-二(芳基氨基)-嘧啶-5-酰胺化合物

Also Published As

Publication number Publication date
WO2008031594A1 (en) 2008-03-20
CA2660987A1 (en) 2008-03-20
UY30587A1 (es) 2008-05-02
EA200900388A1 (ru) 2009-08-28
SMAP200900023A (it) 2009-05-11
ES2377148T3 (es) 2012-03-22
MX2009002812A (es) 2009-03-31
CN101516860A (zh) 2009-08-26
ATE532774T1 (de) 2011-11-15
PL2066647T3 (pl) 2012-04-30
ZA200900477B (en) 2010-01-27
PA8748101A1 (es) 2009-08-26
IL196860A0 (en) 2009-11-18
KR20090064389A (ko) 2009-06-18
AU2007296916A1 (en) 2008-03-20
JP2010503629A (ja) 2010-02-04
CR10639A (es) 2009-07-03
PT2066647E (pt) 2012-01-17
JP5325105B2 (ja) 2013-10-23
BRPI0716841A2 (pt) 2013-10-01
GT200900056A (es) 2011-11-08
PE20080842A1 (es) 2008-08-11
EP2066647A1 (en) 2009-06-10
AR062786A1 (es) 2008-12-03
CO6150142A2 (es) 2010-04-20
NO20091469L (no) 2009-04-15
US8629168B2 (en) 2014-01-14
TW200819444A (en) 2008-05-01
CL2007002669A1 (es) 2008-05-09
MA30723B1 (fr) 2009-09-01
AU2007296916B2 (en) 2011-10-06
EP2066647B1 (en) 2011-11-09
EP1900729A1 (en) 2008-03-19
CN101516860B (zh) 2012-06-27
US20100009978A1 (en) 2010-01-14
TN2009000070A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
SMAP200900023A (it) Benzossazoli e ossazolopiridine utili come inibitori di chinasi janus
FR22C1060I2 (fr) Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases
CY2017012I2 (el) Αναστολεις κινασης τυροσινης bruton
CY2015043I1 (el) Ενωσεις και συνθεσεις ως αναστολεις των πρωτεϊνικων κινασων
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
SM201000108B (it) Composti e composizioni come inibitori di proteinachinasi
SMAP200900020A (it) Composti e composizioni come inibitori di proteinachinasi
SMAP200900031A (it) Composti e composizioni come inibitori di proteinachinasi
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2848610T3 (da) Hæmmere af kinaseaktivitet
DK1898903T3 (da) Inhibitorer af Akt-aktivitet
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
HK1119696A1 (en) Pyridopyrimidinone inhibitors of pi3k pi3k
CR9850A (es) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
BRPI0717411A2 (pt) Uso de inibidores de iap
NO343939B1 (no) Formuleringer av en src/abl-inhibitor
ATE493403T1 (de) Kinaseinhibitoren
DOP2007000082A (es) Inhibidores de quinasas de puntos de control
DK2066662T3 (da) Serinhydrolaseinhibitorer
EP2032141A4 (en) INHIBITORS OF KINASES JANUS
BRPI0923878A2 (pt) Inibidores de giyt1 bicíclicos 3.1.0 e métodos de produção e uso dos mesmos.